Eli Lilly and Company to Issue Quarterly Dividend of $1.73 (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, June 22nd. Stockholders of record on Friday, August 14th will be given a dividend of 1.73 per share on Thursday, September 10th. This represents a c) annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th.

Eli Lilly and Company has raised its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend every year for the last 11 years. Eli Lilly and Company has a payout ratio of 23.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Eli Lilly and Company to earn $44.60 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 15.5%.

Eli Lilly and Company Trading Up 0.5%

Eli Lilly and Company stock opened at $1,103.69 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The firm’s 50 day moving average price is $1,019.04 and its 200-day moving average price is $1,017.54. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market cap of $1.04 trillion, a P/E ratio of 39.21, a PEG ratio of 1.20 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. Guggenheim reiterated a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their target price for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,230.89.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.